Spectral Diagnostics (OTCMKTS:EDTXF) Shares Down 4.8% - Time to Sell?

Key Points

• Spectral Diagnostics Inc. shares fell by 4.8% to $0.59, with a trading volume decline of 94% from its average.
• The company's recent quarterly earnings reported an EPS of (0.03) and revenue of $0.40 million.
• Spectral Diagnostics focuses on developing products for the treatment of septic shock, including the Endotoxin Activity Assay and Polymyxin B Hemoperfusion.

Spectral Diagnostics Inc. (OTCMKTS:EDTXF - Get Free Report) shares dropped 4.8% during mid-day trading on Monday . The stock traded as low as $0.59 and last traded at $0.59. Approximately 750 shares changed hands during trading, a decline of 94% from the average daily volume of 11,951 shares. The stock had previously closed at $0.61.

Spectral Diagnostics Stock Down 4.8%

The company has a 50 day moving average of $0.61 and a 200-day moving average of $0.54. The stock has a market capitalization of $167.20 million, a P/E ratio of -8.36 and a beta of 0.26.

Spectral Diagnostics (OTCMKTS:EDTXF - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $0.40 million during the quarter.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.